Immunotherapy for metastatic non–small cell lung cancer: Is it really a no‐brainer?

There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non–small cell lung cancer (NSCLC); it is very important to expand research in this area because brain metastasis strongly affects patients' quality of l...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Vol. 130; no. 15; pp. 2577 - 2581
Main Authors: Young, Lauren K., Halmos, Balazs
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01.08.2024
Subjects:
Apoptosis
Brain
Brain cancer
Growth factors
Immunotherapy
Kinases
Lung cancer
Lymphoma
Metastases
Monoclonal antibodies
Non-small cell lung carcinoma
Protein-tyrosine kinase
Quality of life
Risk factors
Small cell lung carcinoma
Targeted cancer therapy
ISSN:0008-543X, 1097-0142, 1097-0142
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non–small cell lung cancer (NSCLC); it is very important to expand research in this area because brain metastasis strongly affects patients' quality of life and overall survival. This editorial reviews the available data in the context of a recent meta‐analysis of the pivotal IMpower130, IMpower131, and IMpower150 studies, which explores metastatic epidermal growth factor receptor and anaplastic lymphoma kinase wild‐type NSCLC to determine potential preventative factors and risk factors for the development of brain metastasis, specifically the question of whether immunotherapy (the anti–programmed death ligand 1 antibody, atezolizumab in particular) plays a role in preventing brain metastasis.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ISSN:0008-543X
1097-0142
1097-0142
DOI:10.1002/cncr.35350